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Introduction
The spinal muscular atrophies belong to a heteroge-
neous group of disorders, which are responsible for
early childhood mortality. Proximal SMA is an autoso-
mal recessive neuromuscular disorder, which leads to
symmetrical muscle weakness and atrophy. It has an es-
timated incidence of 1 in 10,000 live births [1], and a car-
rier frequency of 1 in 40. Clinically, proximal SMA is fur-
ther divided into four types based on the age of onset
and severity of the clinical course.Childhood onset SMA
can be classified into three types (Type I–III) [2]. Type
IV SMA is an adult form with onset after 30 years of age
with variable severity. By molecular genetic analysis, all
three forms of childhood SMA were mapped to chro-
mosome 5q11.2-q13.3. In early 1995, two candidate
genes were identified in the telomeric part of critical re-
gion harbouring a large inverted repeat: the survival of
motor neuron 1 (SMN1) gene [3] and the gene encoding
the neuronal apoptosis inhibitor protein (NAIP) gene
[4]. A highly homologous copy of the SMN1 gene, the
survival of motor neuron gene 2 (SMN2) is also present
in the centromeric-most repeat of the chromosome 5.
Lefebvre et al. [3] showed that the SMN1 gene is deleted
or interrupted in 98.6 % of SMA patients. However,
SMN2 is not directly associated with disease because ho-
mozygous deletions of SMN2 gene are also observed in
2–5 % of normal individuals. The high SMN1 deletion
frequency in childhood SMA is supported by many
studies [5–8]. In addition to deletion, the presence of
subtle mutation on one of the chromosomes in a num-
ber of non deletion SMA patients have been described
[5, 6, 9, 10] making SMN1 the responsible gene for prox-
imal SMA. Type IV patients show only 20–30 % ho-
mozygous deletion of SMN1 gene [11, 12].
NAIP, the other candidate gene, shows homology
with a baculoviral inhibitor of apoptosis and inhibits
apoptosis in mammalian cells [13].Absence of homozy-
gous deletions of NAIP was found in 45 % of SMA type I
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■ Abstract In view of the paucity
of deletion studies of survival of
motor neuron (SMN) and neuronal
apoptosis inhibitor protein (NAIP)
genes in Indian SMA patients, this
study has been undertaken to de-
termine the status of SMN1, SMN2
and NAIP gene deletions in Indian
SMA patients. Clinically and neu-
rophysiologically diagnosed SMA
patients were included in the study.
A gene deletion study was carried
out in 45 proximal SMA patients
and 50 controls of the same ethnic
group. Both SMN1 and NAIP genes
showed homozygous absence in
76 % and 31 % respectively in prox-
imal SMA patients. It is proposed
that the lower deletion frequency
of SMN1 gene in Indian patients
may be due to mutations present in
other genes or population varia-
tion, which need further study.
■ Key words SMN1 · SMN2 · NAIP
· spinal muscular atrophy
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patients and in 18 % of type II and III SMA patients [4].
Similar results have been reported by other groups as
well. Deletions in NAIP appear to be associated with in-
creased severity of the disease, although the association
is not absolute [4, 14].
Within the last few years, there have been several re-
ports on SMN and NAIP gene deletions in SMA patients
of different ethnic origins: including French [3],Chinese
[12], African [15], American [16] and many other
groups. However, detailed information pertaining to the
analysis of these genes in clinically diagnosed SMA pa-
tients from India is still lacking. Hence, the aim of our
study was to evaluate the status of SMN and NAIP genes
in Indian patients referred with the diagnosis of proxi-
mal SMA.
Materials and methods
■ Subjects
Patients from January 2000–January 2004 recruited from Genetic and
Neurology outpatients departments (OPD) of Sanjay Gandhi Post-
graduate Institute of Medical Sciences Lucknow, were included in the
study. A detailed clinical evaluation was recorded including age, sex,
age of onset, present status of functional ability, associated features
like respiratory muscle weakness, detailed antenatal history, reduced
fetal movements, feeding difficulties and developmental history.Fam-
ily history and consanguinity was also recorded. The patients with
clinical suspicion of neuromuscular disorders other than proximal
SMA were excluded from this study. Clinical diagnosis of SMA was
based on the criteria of Munsat and Davies (1992) [17]. All patients
showed features consistent with anterior horn cell involvement iden-
tified by neurological examinations,and EMG study carried out at the
centre. The clinical features like symmetrical muscle weakness of
trunk and limbs, proximal muscles weakness more than distal, lower
limbs involvement more than upper limbs, fasciculations of tongue
and tremor of hands were seen in the patients. Muscle biopsies were
carried out in selected cases to confirm the diagnosis. The patients (if
alive) were followed for 1–2 years. Fifty healthy age and sex matched
individuals without any history of neurological disease and normal
on neurological examination were included as controls.
■ Methods
Five ml blood was collected in EDTA tubes from 45 patients and 50
controls. DNA was extracted from blood by the standard salting out
method [18].
Molecular analysis of SMN gene by PCR-RFLP
Polymerase chain reaction was used to amplify exons 7 and 8 of SMN
gene with an initial denaturation at 96 °C for 7 min was followed by 35
cycles (94 °C, 62 °C and 72 °C for 1 min each). The primer sequences
for exons 7 and 8 were taken from Chang et al. (1997) [12]. PCR prod-
ucts of exons 7 and 8 were digested with Dra I and Dde I, respectively.
The digested products were analysed on 10 % Poly acrylamide gel
electrophoresis (PAGE) and photographed by Alpha Imager™ 1220
Documentation and Analysis System (Alpha Innotech Corporation,
USA).
Molecular analysis of NAIP gene by PCR
All individuals were also tested for exon 5 deletion of NAIP gene. PCR
conditions and primers used to amplify the exon 5 were identical to
those of Somerville et al. (1997) [14]. The PCR was started with initial
denaturation at 96 °C for 7 min followed by amplification for 30 cycles
(94 °C, 60 °C and 72 °C for 1.30 min each) followed by a final extension
for 10 min at 72 °C. The PCR products were analysed on 2 % agarose
gel containing ethidium bromide.
Results
■ Clinical Features
Forty five patients with proximal SMA (29 males, 16 fe-
males) compiled with the International inclusion crite-
ria were included in the study. Twelve had type I SMA, 7
type II, 23 type III and 3 type IV SMA. All the patients
and controls were of Indian ethnic origin and 17 were
Muslim. In 8 Muslim patients a history of consan-
guineous marriage was present. The age of onset for
neuromuscular disorder was from infancy to 3 months
of age in type I SMA, 6 to 18 months in type II patients,
2.5 to 30 years in type III and in type IV it ranges from
39 to 58 years. Delayed motor milestones and hypotonia
were observed in all type I patients. All the patients in
the study showed the neurogenic patterns on EMG and
their CPK levels were in normal range (Table 1).
Deletion Analysis of SMN and NAIP gene
The PCR amplification of exon 7 product digested with
Dra I gave three products (188,149 and 39 bp); the 39bp
product runs out of the gel (Fig. 1). Exon 8 PCR product
digested with Dde I gave three products after digestion
Type of SMA Type I Type II Type III Type IV
Age of Onset Birth to 3 Months 6 to 18 Months 2.5 to 30 Years 39 to 58 Years
Sex ratio (M:F) 7:5 4:3 17:6 1:2
Positive family history (n) 8 2 8 0
Consanguinity (n) 3 0 5 0
Ethnicity (Hindu: Muslim) 9:3 5:2 16:7 3:0
EMG Neurogenic Neurogenic Neurogenic Neurogenic
CPK* (IU) 222 (81 to 584) 157 (63–241) 238 (91–882) 204 (178–231)
* Values are in Median (Range), Normal range of CPK (20–200 IU); n Numbers of patients
Table 1 Clinical features of SMA patients
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(187, 123 and 64bp) (Fig. 2). The absence of 188 bp and
187 bp bands showed homozygous deletion of exons 7
and 8 of SMN1 gene respectively (Figs. 1, 2). Out of 45
SMA patients,34 (76 %) showed homozygous deletion of
SMN1 gene. In type I SMA patients, exon 7 of SMN1 gene
was deleted in 91 %. There was slightly higher frequency
of homozygous absence of SMN1 in type III than in type
II SMA patients i. e. 78 % vs 72 %. Absence of both exons
7 and 8 was observed in 31 patients but 3 (9 %) patients
showed only deletion of exon 7, whereas exon 8 of SMN1
gene was present (Table 2). None of Type IV patients
showed homozygous absence of SMN1 gene.None of pa-
tients and controls showed SMN2 gene deletion.
Fourteen (31 %) patients showed deletion of NAIP
gene (Fig. 3). In our study, we observed 58 % of deletion
of NAIP gene in Type I patients, but Type II and III pa-
tients showed 14 % and 26 % deletion respectively. Type
IV patients did not show homozygous absence of NAIP
gene. NAIP deletion in type I, II and III patients is in
concordance with the reported frequency from other
populations.
Discussion
This study examines the clinical and genetic basis of
SMA in Indian patients. It has been the experience of our
laboratory that the clinical symptoms of SMA are not
sufficiently specific to make a reliable diagnosis. EMG
provides good supportive evidence for the diagnosis but
may be inconclusive in some cases. There is no single di-
agnostic test; hence the diagnosis has to be based on
clinical symptoms. Detection of deletion in SMN1 con-
firms the diagnosis of SMA and also provides reason for
prenatal diagnosis. Hence, DNA test for SMN1 deletion
has great importance in diagnosis of SMA.
In our study 76 % of patients with SMA were found to
be homozygous for deletion of SMN1 exon 7 and/or
exon 8 and 31 % were found to be homozygous for NAIP
deletion. The majority of type I patients showed large
deletions of SMN1 and NAIP, whereas most of type II
and III show deletions of SMN1 only. All the NAIP
deleted samples also showed deletion of SMN1 gene. In
none of our patients was NAIP deletion without SMN1
gene deletion detected. Since NAIP deleted individuals
were a subset of those who had the SMN1 gene deletion,
so NAIP deletion does not appear to be an independent
risk factor for SMA [19].
In our study,91 % of clinically defined type I SMA pa-
tients lacked both copies of SMN1, compared with 78 %
and 72 % of type III and type II patients. In an earlier
study from India, Dua et al. [20] reported approximately
55 % of floppy infants with clinical features of SMA had
homozygous deletion of exon 7 of SMN1 gene. There
may be several reasons for the variation in the frequency
of SMN1 gene deletion in different studies. First, SMA is
a part of a wide spectrum of anterior horn cells disor-
ders that affect infants and young children and clinical
Fig. 1 Exon 7 PCR-RFLP. Polyacrylamide gel photograph showing the undigested
and digested products of SMN exon 7 after Dra I digestion. Lane 1, 3 undigested
product of patient; lane 2, digested product of patient with SMN1 deletion; lane 4,
digested product of patient without SMN1 gene deletion; Lane 5, undigested prod-
uct of control; Lane 6, digested product of control with no SMN1 deletion. Lane 7,
50 bp DNA ladder.
Table 2 Deletion analysis results of SMN1 and NAIP gene in SMA patients
Proximal SMA Number Status of SMN1 Status of NAIP
(n = 45) of patients gene Deletion gene Deletion
SMA I 12 11 (91%) 7 (58%)
SMA II 7 5 (72%)a 1 (14%)
SMA III 23 18 (78%)b 6 (26%)
SMA IV 3 0 0
a two patients had deletion of exon 7 only; b one patient had deletion of exon 7 only
n Number of patients
Fig. 2 Exon 8 PCR-RFLP. Polyacrylamide gel photograph showing the undigested
and digested products of SMN exon 8 after Dde I digestion. Lane 1, undigested PCR
product of SMA patient; lane 2 digested product of patient with SMN1 gene dele-
tion; Lane 3, undigested product of normal control; lane 4 digested product of con-
trol without SMN1 deletion. Lane 5, 50 bp DNA ladder
Fig. 3 Agarose gel photograph showing the products of NAIP-PCR. Lanes 1, 3 are
type I patients with NAIP deletion. Lanes 2, 4 are type III patients with no deletion
of NAIP gene. Lane 5 is type II SMA patient with NAIP gene deletion. Lane 6 is con-
trol sample.
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symptoms are overlapping and may not be sufficiently
specific to make a reliable diagnosis of SMA. Patients
who are referred for molecular diagnosis generally have
symptoms, like hypotonia, proximal muscle weakness,
and loss of ambulation.These symptoms are not specific
to 5q linked SMA and in infants there are additional
complications. Muscle testing and EMG examination at
times may be difficult in a neonate to perform. This may
be one of the reasons for discrepancy in the deletion fre-
quency in our patients group. The other reason for the
difference in the frequency may be the population vari-
ation as in South African black patients 65 % [21] had
deletion, Saudi Arabian patients had 72 % deletion [22],
Polish had 63 % [23] and Vietnamese showed 41 % [24]
deletion, while many other studies showed more than
90 % of deletion in SMN1 gene.
We have observed that 2 of our type II patients and 1
of type III patient had deletion of exon 7 only but re-
taining exon 8 of SMN1 gene, this may be due to a gene
conversion event at this locus. The gene conversion
event is more common in type II and III patients, than
in type 1 SMA patients [25, 26]. Large deletions in type
1 patients may result from unequal cross-over of repeat
units at SMN locus whereas gene conversion in type II
and III SMA may be facilitated by sequence homology
between SMN1 and SMN2 genes
Only 31 % of the patients with SMA were found to
have deletion of NAIP gene. In type I SMA higher per-
centage (58 %) of NAIP deletion has been observed as
compared with type II and III SMA (Table 2). NAIP gene
deletions frequencies in our patients are in concordance
with the reported frequency from other populations [7,
27]. From the data, it is clear that NAIP deleted individ-
uals are a subset of those who also have the SMN1 gene
deletion. NAIP gene deletion was not present in all type
I patients and it was not absent in all type II and type III
patients, as 14 % and 26 % of type II and type III patients
had deletion of NAIP gene. NAIP was not deleted in
many of type I patient despite a severe course and early
onset of disease. Our data thus substantiate the view that
majority of type I SMA cases result from large deletions
encompassing both SMN and NAIP gene but it does not
support the role of NAIP in disease severity. Taylor et al.
[28] have shown that small mutations within the SMN1
gene do not disrupt NAIP but may still give rise to severe
phenotype. These results suggest that NAIP may not
have a direct role in SMA severity but simply delimits
the extent of deletion within the SMA region [29]. We
agree with others studies [25] that NAIP may be coinci-
dentally deleted with SMN gene.
The primary defect in SMA lies in the anterior horn
cells.A subset of SMA patients present at birth with con-
tractures and muscle atrophy, suggesting a defect in the
development of anterior horn cells or early degenera-
tion. There exists a small but significant number of neu-
romuscular disorders that fulfil the criteria for the diag-
nosis of SMA but have added features leading to
uncertainty as to whether they are the same or different
diseases. By detecting a mutation of SMN1 gene on the
long arm of chromosome 5, it became possible to con-
firm the diagnosis of proximal spinal muscular atrophy.
Point mutations have been reported in 3–4 % of patients
without homozygous deletion of SMN1 gene [2, 3]. A
negative result for homozygous absence of SMN1 de-
creases, but cannot entirely exclude, the probability that
the patient has 5q linked SMA. It is possible that some of
our patients may have mutations, which are present in
other genes yet to be identified.
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